Molecularly Aided Stratification for Tumor Eradication Research

Recruiting now

Conditions studied: Rare Cancers, Multiomics

In brief

NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.

Key facts

Study ID

NCT05852522

Run by

German Cancer Research Center

People needed

10000

Starts

2018-11-11

Expected to finish

2029-10-01

Last updated by the study team

2025-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Rare cancer (Incidence <6/100,000 persons/year) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation)
• Metastatic and/or locally advanced cancer with no curative therapy option and indication for systemic therapy

You may not qualify if…

• Severe neurological or psychiatric disorder interfering with the ability to give oral and written informed consent

Where it is running

• German Cancer Research Center — Heidelberg, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.